NCT05062200View on ClinicalTrials.gov

A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

September 28, 2022

Study Completion Date

September 28, 2022

Conditions
Healthy
Interventions
DRUG

JNJ-77242113

JNJ-77242113 will be administered as an oral tablet.

DRUG

Placebo

Matching placebo will be administered as an oral tablet.

Trial Locations (1)

812-0025

Souseikai Hakata Clinic, Fukuoka

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY